Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection.

Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection.

Publication date: Feb 20, 2024

The endemic human coronaviruses (HCoVs) circulate worldwide yet remain understudied and unmitigated. The observation of elevated levels of HCoV reactive antibodies in COVID-19 patients highlights the urgent necessity of better understanding of HCoV specific immunity. Here, we characterized in-depth the de novo SARS-CoV-2 specific antibody responses and the boosting of HCoV-reactive antibodies after SARS-CoV-2 vaccination or infection in individuals up to 98 years old. All the vaccinees were home-dwelling with no documented SARS-CoV-2 infection before receiving the COVID-19 mRNA vaccine (BNT162b2). The first two vaccine doses elicited potent SARS-CoV-2 spike binding antibodies in individuals up to 80 years. The third dose largely boosted the previously low S2 domain binding and neutralizing antibodies in elderly 80-90 years old, but less so in those above 90 years. The endemic betacoronavirus (HKU1 and OC43) reactive antibodies were boosted in all vaccinees, although to a lesser extent in those above 80 years old. COVID-19 patients had potent elevation of alpha- and betacoronavirus (229E, NL63, HKU1 and OC43) reactive antibodies. In both patients and vaccinees, S2 domain specific antibody increases correlated with SARS-CoV-2 neutralizing and HCoV-reactive antibody responses in all ages, indicating S2 domain as a candidate for future universal coronavirus vaccine design.

Open Access PDF

Concepts Keywords
Bnt162b2 Antibodies
Boosting Antibody
Coronaviruses Coronavirus
Elderly Cov
Vaccination Covid
Domain
Infection
Old
Reactive
Sars
Specific
Vaccination
Vaccine
Vaccinees
Years

Semantics

Type Source Name
disease VO vaccination
disease MESH infection
disease MESH COVID-19
drug DRUGBANK Tropicamide
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccine
disease VO dose
disease VO Betacoronavirus
disease VO coronavirus vaccine
disease MESH common cold
disease MESH critically ill
disease VO vaccine strain
disease MESH Middle East respiratory syndrome
disease IDO blood
drug DRUGBANK Coenzyme M
disease VO vaccine dose
disease VO Viruses
disease IDO susceptibility
disease VO vaccine efficacy
disease VO effectiveness
disease VO population
disease VO CoronaVac
disease VO effective
disease VO vaccine effectiveness
disease VO immunization
disease VO time
disease VO unvaccinated
disease MESH complications
disease VO vaccinee
disease IDO symptom
disease IDO history
drug DRUGBANK Sodium Chloride
disease VO injection

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *